Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

NCT06245291 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Hepatitis B, Chronic

Interventions

DRUG: Imdusiran
DRUG: Durvalumab

Sponsor

Arbutus Biopharma Corporation